DEVELOPING G PROTEIN-COUPLED RECEPTOR, RXFP4, AGONISTS AS NOVEL THERAPEUTICS FOR CHRONIC CONSTIPATION
Grant number: 1182996 | Funding period: 2020 - 2023
Related publications (5)
A Novel Antagonist Peptide Reveals a Physiological Role of Insulin-Like Peptide 5 in Control of Colorectal Function
RV Pustovit, X Zhang, JJM Liew, P Praveen, M Liu, A Koo, L Oparija-Rogenmozere, Q Ou, M Kocan, S Nie, RAD Bathgate, JB Furness, MA Hossain
Insulin-like peptide 5 (INSL5), the natural ligand for the relaxin family peptide receptor 4 (RXFP4), is a gut hormone that is exc..
Human Insulin-like Peptide 5 (INSL5). Identification of a Simplified Version of Two-Chain Analog A13
Xiaozhou Zhang, Ross AD Bathgate, Mohammed Akhter Hossain
The receptor for insulin-like peptide 5 (INSL5), RXFP4, is a potential pharma target for treating human conditions such as constip..
Colokinetic effect of an insulin-like peptide 5-related agonist of the RXFP4 receptor
Shanti Diwakarla, Ross AD Bathgate, Xiaozhou Zhang, Mohammed Akhter Hossain, John B Furness
BACKGROUND: Insulin-like peptide 5 (INSL5) is a hormone stored in colonic enteroendocrine cells that also contain the unrelated ho..
Signal transduction pathways activated by insulin-like peptide 5 at the relaxin family peptide RXFP4 receptor
Sheng Y Ang, Dana S Hutchinson, Nitin Patil, Bronwyn A Evans, Ross AD Bathgate, Michelle L Halls, Mohammed A Hossain, Roger J Summers, Martina Kocan
BACKGROUND AND PURPOSE: Insulin-like peptide 5 (INSL5) is a two-chain, three-disulfide-bonded peptide of the insulin/relaxin super..